Our dynamic research and development abilities have enabled us to manufacture and export a quality range of Bicalutamide Tablets USP. Our tablets are highly effective in bicalutamide therapy. The tablets are formulated under the strict guidance of the expert professionals using finest quality compounds, which we obtain from authorized vendors. We check the Bicalutamide Tablets USP 50mg on purity and quality parameters to offer a defect free range to the clients at the market leading prices.
Longer shelf life
Highly pure quality
For the treatment of Stage D2 metastatic carcinoma of the prostate cancer in combination with a Luteinizing hormone - releasing hormone (LHRH) analog.
The ideal dose for bicalutamide therapy with an LHRH analog is one 50 mg tablet once daily (morning or evening) without regard to meals.